section name header

Basics ⬇

Description
Epidemiology

Incidence

Seen in 1–4% of general anesthetic cases

Prevalence

More common in pediatrics; 40–50% of cases are seen in patients less than 10 years of age.

Morbidity

Associated with MH. 40–50% of trismus patients have a positive halothane contracture test.

Mortality

  • Death in less than 1% from lost airway
  • One to five percent mortality from treated MH.
Etiology/Risk Factors
Physiology/Pathophysiology
Preventative Measures

Diagnosis ⬆ ⬇

Differential Diagnosis

Treatment ⬆ ⬇

Follow-Up ⬆ ⬇

References ⬆ ⬇

  1. Glahn KPE , Ellis FR , Halsall PJ , et al. Recognizing and managing a malignant hyperthermia crisis: Guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105(4):417–420.
  2. Litman RS , Rosenberg H. Malignant hyperthermia. JAMA. 2005;293(23):2918–2924.
  3. Rosenburg H. Trismus is not trivial. Anesthesiology. 1987;67(4):453–455.
  4. Schwartz L , Rockoff MA , Koka BV. Masseter spasm with anesthesia. Anesthesiology. 1984;61(6):772–775.
  5. Shulman DH , Shipman B , Willis FB. Treating trismus with dynamic splinting: A cohort case report. Adv Ther. 2008;25(1):9–16.
  6. Van der Spek AF , Fang WB , Ashton-Miller JA , et al. The effects of succinylcholine on mouth opening. Anesthesiology. 1987;67(4):459–465.

Additional Reading ⬆ ⬇

See Also (Topic, Algorithm, Electronic Media Element)

Codes ⬆ ⬇

ICD9
ICD10

Clinical Pearls ⬆ ⬇

Author(s) ⬆

Thomas I.EppersonIII, MD

Joseph R. Whiteley , DO